DEF: AN2 Therapeutics Sets June 3, 2026 Annual Meeting Date

AN2 Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify auditors.

Summary

• AN2 Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on June 3, 2026, at 8:00 a.m. Pacific Time in Menlo Park, California.
• The meeting agenda includes the election of three Class I directors: Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., for three-year terms.
• Stockholders will also vote on the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The record date for determining stockholders entitled to vote is April 15, 2026.
• Proxy materials will be made available online on or around April 22, 2026, with instructions for voting via internet, telephone, or mail.
• The company's Board of Directors recommends a vote FOR the election of all director nominees and FOR the ratification of the independent auditor.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine proxy statement for an annual meeting and does not contain financial performance data or strategic updates that would typically influence sentiment.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing corporate operations and governance.
• The board has nominated experienced individuals for director positions, with detailed qualifications provided.
• The company continues to engage with its independent auditor, PricewaterhouseCoopers LLP, suggesting a stable financial reporting process.
• Clear instructions are provided for stockholders to vote, ensuring participation in corporate governance.
• The company is utilizing cost-effective methods for distributing proxy materials by providing online access.

Negatives

• The filing does not contain any financial performance data or strategic updates, as it is solely a proxy statement for the annual meeting.
• The company's stock price performance is not discussed, nor are any recent financial results presented.

Risks

• The staggered board structure means that a complete change in board composition requires at least two annual meetings.
• The company's bylaws and SEC rules impose strict deadlines for submitting stockholder proposals and director nominations for future meetings.
• Potential for broker non-votes on non-routine matters, such as director elections, if beneficial owners do not provide voting instructions.

Future Outlook

The filing is a proxy statement for an upcoming annual meeting and does not contain specific forward-looking financial guidance. It outlines the proposals to be voted on at the meeting and the procedures for future stockholder proposals.

Management Comments

• "Your vote is important. Whether or not you plan to attend the Annual Meeting, we hope you will vote as soon as possible."
• "Voting over the internet or by written proxy will ensure your representation at the Annual Meeting regardless of whether you attend in person."
• "Thank you for your ongoing support of and continued interest in AN2 Therapeutics, Inc."
• "We are pleased to take advantage of Securities and Exchange Commission (the SEC) rules that allow us to furnish these proxy materials and our annual report to stockholders on the internet."
• "Your vote is very important. Whether or not you plan to attend the Annual Meeting, we encourage you to read this proxy statement and submit your proxy or voting instructions as soon as possible."

Industry Context

StockSavvy.ai notes that proxy statements are standard filings for publicly traded companies, particularly around annual meetings. The focus on director elections and auditor ratification is typical for maintaining corporate governance and regulatory compliance within the biotechnology and pharmaceutical sector.

Corporate Governance

Related Party Transactions

• Lucy Day's spouse, Senior Director of IT and Operations, received approximately $350,000 in compensation in 2025 and $320,000 in 2024. This relationship was ratified by the audit committee.
• The company entered into a Global Health Agreement with Adjuvant Global Health Technology Fund, L.P. (Adjuvant) in November 2019, amended in March 2021, related to supporting the creation of innovative and affordable drugs for public health programs in low and low-middle-income countries, specifically including the development of epetraborole for tuberculosis-endemic regions.
• Certain holders of capital stock, including entities affiliated with Adjuvant, MGC Venture Partners, Anacor, and Brii Biosciences, are party to an amended and restated investors rights agreement, which includes registration rights.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, influencing corporate governance and oversight.
• Employees: The compensation committee reviews executive compensation and benefit programs, impacting employee incentives and retention.
• Management: Executive compensation is detailed, including base salaries, bonuses, and equity awards, with severance and change-in-control benefits outlined.

Next Steps

• Stockholders are encouraged to vote their shares for the upcoming Annual Meeting.
• The company will file a Current Report on Form 8-K with preliminary voting results within four business days after the Annual Meeting.
• Stockholder proposals for the 2027 Annual Meeting must be received by December 23, 2026, for inclusion in proxy materials.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial information, strategic updates, or material events that would warrant a change in investment recommendation. The focus is on governance matters, director elections, and auditor ratification, which are standard procedures for public companies.

Keywords

Proxy Statement, Annual Meeting, AN2 Therapeutics, Director Election, Independent Auditor, Stockholder Vote, Corporate Governance, DEF 14A